Menu
Back to Archived Journals » Neurobehavioral HIV Medicine » Volume 2
A guide to interpretation of neuroimmunological biomarkers in the combined antiretroviral therapy-era of HIV central nervous system disease
Authors Morris KA, Davies NW, Brew B
Published 24 August 2010 Volume 2010:2 Pages 59—72
DOI https://doi.org/10.2147/NBHIV.S7167
Review by Single anonymous peer review
Peer reviewer comments 3
Katrina A Morris, Nicholas WS Davies, Bruce J Brew
Department of Neurology, St. Vincent’s Hospital, Sydney, Australia and St. Vincent’s Centre for Applied Medical Research, Sydney, New South Wales, Australia
Abstract: Biomarkers have emerging roles in diagnosis, prognostication, and treatment monitoring in patients with human immunodeficiency virus-related central nervous system disease. Currently, it is unlikely that a single biomarker will be able to fulfill these roles; rather a combination is more likely. In this review, we use a pathogenetic framework to discuss biomarkers derived from both the blood and cerebrospinal fluid. Emphasis is given to those biomarkers that have a more solid evidence base and those that are easily measurable.
Keywords: CSF, biomarker, HAND, HIV, CART
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.